Ignite Creation Date:
2025-12-24 @ 5:03 PM
Ignite Modification Date:
2025-12-27 @ 5:22 AM
Study NCT ID:
NCT03953950
Status:
UNKNOWN
Last Update Posted:
2019-09-04
First Post:
2019-04-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007676', 'term': 'Kidney Failure, Chronic'}], 'ancestors': [{'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013148', 'term': 'Spironolactone'}, {'id': 'D019808', 'term': 'Losartan'}], 'ancestors': [{'id': 'D007783', 'term': 'Lactones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011283', 'term': 'Pregnenes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D001713', 'term': 'Biphenyl Compounds'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D007093', 'term': 'Imidazoles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D013777', 'term': 'Tetrazoles'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 84}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2019-10', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-08', 'completionDateStruct': {'date': '2020-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-08-30', 'studyFirstSubmitDate': '2019-04-20', 'studyFirstSubmitQcDate': '2019-05-15', 'lastUpdatePostDateStruct': {'date': '2019-09-04', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-05-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Changes in blood pressure', 'timeFrame': '6 months'}, {'measure': 'Incidence of PD technique failure', 'timeFrame': '6 months'}, {'measure': 'Incidence of PD-related infections', 'timeFrame': '6 months', 'description': 'Peritonitis or exit-site and tunnel infection'}, {'measure': 'Number of participants with investigational medicinal products-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '6 months', 'description': 'Safety of investigational medicinal products related to potential harm (e.g. death, hospitalization, and emergency visit)'}], 'primaryOutcomes': [{'measure': 'Peritoneal dialysate effluent CA-125', 'timeFrame': '6 months', 'description': 'Using a commercial microparticle enzyme-linked immunosorbent assay'}, {'measure': 'PET indices', 'timeFrame': '6 months', 'description': 'PET indices including dialysate-to-plasma creatinine ratio \\[D/P Cr\\], 4-hour ultrafiltration (UF) volume, and the concentration of glucose present in the solution at the start of the test \\[D/D0\\]) measured using a modified PET method (performed using 2,000 mL of 2.5% glucose solution).'}], 'secondaryOutcomes': [{'measure': 'Changes in dialysate adequacy by Weekly kt/V', 'timeFrame': '6 months'}, {'measure': 'Changes in dialysate adequacy by weekly creatinine clearance', 'timeFrame': '6 months'}, {'measure': 'Changes in serum albumin concentration', 'timeFrame': '6 months'}, {'measure': 'Changes in serum potassium concentration', 'timeFrame': '6 months'}, {'measure': 'Changes in waist circumference', 'timeFrame': '6 months'}, {'measure': 'Changes in body mass index (BMI)', 'timeFrame': '6 months', 'description': 'Weight and height will be combined to report BMI in kg/m\\^2'}, {'measure': 'Changes in Nutritional status', 'timeFrame': '6 months', 'description': 'Using Subjective Global Assessment (SGA)'}, {'measure': 'Changes in Malnutrition-Inflammation Score (MIS)', 'timeFrame': '6 months'}, {'measure': 'Changes in participant quality of life score', 'timeFrame': '6 months', 'description': 'Using Kidney Disease Quality of Life-36 (KDQOL-36 Version 1.3)'}, {'measure': 'Changes in health utility', 'timeFrame': '6 months', 'description': 'Using EuroQOL-5 dimension 5-level (EQ-5D-5L)'}, {'measure': 'Changes in disease-specific Thai quality of life score', 'timeFrame': '6 months', 'description': 'Using the 9-Thai Health status AssessmentInstrument (9-THAI) questionnaire'}, {'measure': 'Changes in participant well-being score', 'timeFrame': '6 months', 'description': 'Using the World Health Organization-Five (WHO-5) well-being index'}, {'measure': 'Number of participants with disability', 'timeFrame': '6 months', 'description': 'Using the Barthel activities daily life index'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Peritoneal Dialysis', 'Peritoneal Membrane', 'Spironolactone', 'Losartan', 'Renin-Angiotensin-Aldosterone System'], 'conditions': ['End Stage Renal Disease', 'Peritoneal Dialysis']}, 'referencesModule': {'references': [{'pmid': '33586138', 'type': 'DERIVED', 'citation': 'Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021 Feb 15;2(2):CD013109. doi: 10.1002/14651858.CD013109.pub2.'}]}, 'descriptionModule': {'briefSummary': 'The ESCAPE-PD (Effects of add-on SpironolaCtone to losartan versus Alone on Peritoneal mEmbrane among continuous ambulatory Peritoneal Dialysis patients) study is a randomized, open-label, single center, active-controlled clinical trial. Adults end-stage kidney disease patients 18 years or older undergoing continuous ambulatory peritoneal dialysis (CAPD) will be enrolled. A total 84 CAPD will be randomly assigned to either the combination of spironolactone and losartan (experimental arm) or losartan alone (control arm). The primary outcomes are the difference in peritoneal dialysate effluent cancer antigen-125 (CA-125) and peritoneal equilibration test (PET) indices (dialysate-to-plasma creatinine ratio, 4-hour ultrafiltration volume, and the concentration of glucose present in the solution at the start of the test). Secondary outcome measures include laboratory and mechanistic outcome measures, nutrition outcomes, health-related quality of life, physical function, clinical events, and safety profiles. Results will be disseminated to suggest a strategy to prevent the peritoneal membrane function among CAPD patients through peer-reviewed publications along with scientific meetings.', 'detailedDescription': 'Peritoneal dialysis (PD) is one of the methods of renal replacement therapy (RRT) that can easily perform at home. The declared "PD first" policy from the National Health Security Office causes rapidly expansion of this group of patients. In the year 2013, the current study in Thailand showed that the patients enrolled for peritoneal dialysis accumulated for more than 15,000 people. It works continuously similar to the actual function of the kidneys in normal people. In addition, PD also helps to slow the decline of remaining kidney function (residual renal function), which is very important and affect in decreasing mortality rate in this group of patients. However, PD has several limitations such as complications from the infection and high failure rate associated with a dysfunction of the peritoneal membrane during long-term treatment. Approximately 4-12 percent of patients will have ultrafiltration failure and volume overload in the first couple of years of treatment and soar to 30-50 percent in patients treated for more than six years.\n\nThe causes of peritoneal membrane deterioration are exposure to incompatible dialysis solution with hyperosmolar glucose content, acidic pH, reactions to PD catheter material, uremia and peritonitis. The alterations of structural and functional of the peritoneal membrane after exposed to these several insults are epithelial-to-mesenchymal transition (EMT), and increase in peritoneal solute transport, which consequently leading to peritoneal dialysis failure. It has been already demonstrated that the local renin-angiotensin-aldosterone system (RAAS) plays a key role in this regulation by promoting the activation of neoangiogenesis and fibrotic pathways.\n\nAccording to the pathophysiologic changes of the peritoneal membrane, Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) are adapted to be use in respect of membrane preserving agents. Many studies, both in human and animal models, demonstrate the protective effect against peritoneal membrane deterioration by inhibiting the formation of transforming growth factor beta1 (TGF-β1), vascular endothelial growth factor (VEGF), and decreasing progression rate of small to high transport membrane type. In fact, mineralocorticoid receptor antagonists (MRAs) seem to have higher efficacy than ACEIs/ARBs in some experimental models. The possible mechanism is the effects of mineralocorticoid receptor antagonists that not only inhibit the formation of TGF- β1 and VEGF, but also suppress intracellular Reactive Oxygen Species (ROS) generation, activation of extracellular signal-regulated kinase (ERK) 1/2, and p38 mitogen-activated protein kinase (MAPK), the substrates responsible for aldosterone induces alterations in cell phenotype. A prospective cohort study of 23 CAPD patients was conducted and evaluated the effect of spironolactone on peritoneal membrane. The result showed the possible benefit of spironolactone in slowing the decline of peritoneal function, suppressing the elevation of profibrotic markers, and increasing mesothelial cell mass.\n\nAs a result of the clinical practice, most of CAPD patients tend to receive ACEIs/ARBs as prescribe by the clinicians, in order to control blood pressure, raise serum potassium level, and others compelling indications. Thus, the concept of add-on MRAs to ACEIs/ARBs, desiring the synergistic effects of these 2 drugs group, for membrane preservation is challenge. Notwithstanding the fact that current evidence about the combination effects of ACEIs/ARBs with MRAs is limited in term of quality of the study, sample size, inadequate follow-up period, and poor sensitive parameter in assessing the structural and functional changes of the peritoneal membrane. Thereby, this study aims to evaluate the effect of add-on spironolactone to losartan versus losartan alone on membrane preservation in continuous ambulatory peritoneal dialysis patients.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Age ≥ 18 years or older (both male and female patients)\n* Incidence or prevalent end-stage kidney disease patients undergoing CAPD\n* Had standard dialysis prescription for at least 30 days before screening\n* History of hypertension\n* Stable clinical condition without any inflammation at least 4 weeks prior to enrolment\n* Had an ability to understand and willingness to sign an informed consent statement\n\nExclusion Criteria:\n\n* Serum potassium concentration of ≥ 5.5 milliequivalent /liter\n* History of severe or active cardiovascular and/or cerebrovascular disease\n* History of renal artery stenosis\n* Uncontrolled hypertension\n* Contraindication to angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers or mineralocorticoid receptor antagonists\n* Pregnancy\n* Recent PD-related peritonitis or exit-site and tunnel infection (within 2 months of screening)\n* Had planned to have kidney transplantation or transfer to other PD centers with 6 months\n* Prognosis for survival less than 12 months\n* Any conditions (both mental or physical) that would interfere with the participant's ability to comply with the study protocol\n* Any disease of the abdominal wall, such as injury or surgery, burns, hernia, dermatitis, inflammatory bowel diseases (Crohn's disease, ulcerative colitis or diverticulitis) that in the opinion of the Investigator would preclude the patient from being able to have PD\n* Any intra-abdominal tumors or intestinal obstruction\n* Current or recent (within 30 days) exposure to others investigational medicinal products"}, 'identificationModule': {'nctId': 'NCT03953950', 'acronym': 'ESCAPE-PD', 'briefTitle': 'Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients', 'organization': {'class': 'OTHER', 'fullName': 'Chiang Mai University'}, 'officialTitle': 'Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial', 'orgStudyIdInfo': {'id': 'THOR Study Group'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Combination of spironolactone and losartan', 'interventionNames': ['Drug: Spironolactone', 'Drug: Losartan']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Losartan Alone', 'interventionNames': ['Drug: Losartan']}], 'interventions': [{'name': 'Spironolactone', 'type': 'DRUG', 'description': 'Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\\< 140/90 mmHg, but avoid hypotension \\<90/60 mmHg), and serum potassium level (\\<5.5 milliequivalent /liter)', 'armGroupLabels': ['Combination of spironolactone and losartan']}, {'name': 'Losartan', 'type': 'DRUG', 'description': 'Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep\\< 140/90 mmHg, but avoid hypotension \\<90/60 mmHg), and serum potassium level (\\<5.5 milliequivalent /liter)', 'armGroupLabels': ['Combination of spironolactone and losartan', 'Losartan Alone']}]}, 'contactsLocationsModule': {'locations': [{'zip': '50200', 'city': 'Chiang Mai', 'country': 'Thailand', 'facility': 'Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chiang Mai University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Chidchanok Ruengorn', 'investigatorAffiliation': 'Chiang Mai University'}}}}